View in EDS

Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers.

Saved in:
Bibliographic Details
Title: Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers.
Authors: Haykal MM; Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et Nouvelles Stratégies Thérapeutiques en Oncologie, 94800, Villejuif, France; Université Paris-Saclay, 91400, Orsay, France., Rodrigues-Ferreira S; Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et Nouvelles Stratégies Thérapeutiques en Oncologie, 94800, Villejuif, France; Université Paris-Saclay, 91400, Orsay, France; Inovarion, 75005, Paris, France., El Botty R; Translational Research Department, Institut Curie, PSL University, 75005, Paris, France., Sourd L; Translational Research Department, Institut Curie, PSL University, 75005, Paris, France., Marangoni E; Translational Research Department, Institut Curie, PSL University, 75005, Paris, France., Varin M; IKTOS, 75017, Paris, France., Denis A; IKTOS, 75017, Paris, France., Nahmias C; Institut Gustave Roussy, Inserm U981, Biomarqueurs prédictifs et Nouvelles Stratégies Thérapeutiques en Oncologie, 94800, Villejuif, France; Université Paris-Saclay, 91400, Orsay, France. Electronic address: clara.nahmias@inserm.fr.
Source: Cancer letters [Cancer Lett] 2025 Jun 28; Vol. 620, pp. 217665. Date of Electronic Publication: 2025 Mar 22.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 7600053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7980 (Electronic) Linking ISSN: 03043835 NLM ISO Abbreviation: Cancer Lett Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1872-7980
DOI:10.1016/j.canlet.2025.217665